FATE
Price
$1.27
Change
+$0.02 (+1.60%)
Updated
Jan 17 closing price
Capitalization
144.65M
44 days until earnings call
SPRB
Price
$0.36
Change
-$0.02 (-5.26%)
Updated
Jan 17 closing price
Capitalization
15.07M
53 days until earnings call
Ad is loading...

FATE vs SPRB

Header iconFATE vs SPRB Comparison
Open Charts FATE vs SPRBBanner chart's image
Fate Therapeutics
Price$1.27
Change+$0.02 (+1.60%)
Volume$1.27M
Capitalization144.65M
Spruce Biosciences
Price$0.36
Change-$0.02 (-5.26%)
Volume$456.89K
Capitalization15.07M
FATE vs SPRB Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. SPRB commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and SPRB is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (FATE: $1.27 vs. SPRB: $0.36)
Brand notoriety: FATE and SPRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 32% vs. SPRB: 64%
Market capitalization -- FATE: $144.65M vs. SPRB: $15.07M
FATE [@Biotechnology] is valued at $144.65M. SPRB’s [@Biotechnology] market capitalization is $15.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileSPRB’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • SPRB’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and SPRB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while SPRB’s TA Score has 5 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 3 bearish.
  • SPRB’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, SPRB is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -13.31% price change this week, while SPRB (@Biotechnology) price change was -1.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

FATE is expected to report earnings on Apr 30, 2025.

SPRB is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($145M) has a higher market cap than SPRB($15.1M). SPRB YTD gains are higher at: -13.143 vs. FATE (-23.030). SPRB has higher annual earnings (EBITDA): -39.02M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. SPRB (60.1M). SPRB has less debt than FATE: SPRB (3.23M) vs FATE (99M). FATE has higher revenues than SPRB: FATE (13.4M) vs SPRB (7.1M).
FATESPRBFATE / SPRB
Capitalization145M15.1M960%
EBITDA-177.57M-39.02M455%
Gain YTD-23.030-13.143175%
P/E RatioN/AN/A-
Revenue13.4M7.1M189%
Total Cash297M60.1M494%
Total Debt99M3.23M3,065%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATESPRB
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
89%
Bullish Trend 11 days ago
85%
Momentum
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 11 days ago
82%
MACD
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 11 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
84%
Bearish Trend 11 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
88%
Advances
ODDS (%)
Bullish Trend 13 days ago
86%
Bullish Trend 23 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
85%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMOUX25.140.14
+0.56%
GMO International Equity I
JMNSX15.720.05
+0.32%
JPMorgan Research Market Neutral I
MFWTX16.430.05
+0.31%
MFS Global Total Return A
AVEWX20.150.06
+0.30%
Ave Maria World Equity
ANOGX23.740.07
+0.30%
American Century Small Cap Growth R5

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+1.60%
ALLO - FATE
57%
Loosely correlated
-1.09%
RCKT - FATE
52%
Loosely correlated
+0.98%
CRSP - FATE
51%
Loosely correlated
+0.57%
CRBU - FATE
50%
Loosely correlated
-0.65%
NTLA - FATE
50%
Loosely correlated
+0.85%
More

SPRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRB has been loosely correlated with MLEC. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRB jumps, then MLEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRB
1D Price
Change %
SPRB100%
-4.75%
MLEC - SPRB
51%
Loosely correlated
-1.29%
IMRX - SPRB
51%
Loosely correlated
+3.06%
FATE - SPRB
45%
Loosely correlated
+1.60%
SCPX - SPRB
43%
Loosely correlated
-1.86%
GNFT - SPRB
39%
Loosely correlated
+0.73%
More